European Leukemia Trial Registry
Trial: Gilead GS-US-352-1214

More Details
Title Phase III Study with Momelotinib versus BAT in patients with PMF, Post-PV, Post-ET after treatment with Ruxolitinib
Scientific Title A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib
Short Title Gilead GS-US-352-1214
Trialgroup NN
Type of Trial randomized
Disease Myeloproliferative disease(MPD) Myelofibrosis
Age -
Status Active
Start of Recruitment 28.03.2014
Leader Griesshammer, Prof. Dr. med., Martin
Shortprotocol Shortprotocol
created 03.09.2014 Johannes Kraus
changed 02.04.2015 Hanna Ebert
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |